189 related articles for article (PubMed ID: 36070626)
21. Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.
Kalnin K; Tibbitts T; Yan Y; Stegalkina S; Shen L; Costa V; Sabharwal R; Anderson SF; Day PM; Christensen N; Schiller JT; Jagu S; Roden RB; Almond J; Kleanthous H
Vaccine; 2014 Jun; 32(28):3540-7. PubMed ID: 24780250
[TBL] [Abstract][Full Text] [Related]
22. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
[TBL] [Abstract][Full Text] [Related]
23. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
24. Optimization of multimeric human papillomavirus L2 vaccines.
Jagu S; Kwak K; Karanam B; Huh WK; Damotharan V; Chivukula SV; Roden RB
PLoS One; 2013; 8(1):e55538. PubMed ID: 23383218
[TBL] [Abstract][Full Text] [Related]
25. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.
Connolly K; Manders P; Earls P; Epstein RJ
Cancer Treat Rev; 2014 Mar; 40(2):205-14. PubMed ID: 24051018
[TBL] [Abstract][Full Text] [Related]
26. Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.
Farmer E; Cheng MA; Hung CF; Wu TC
Recent Results Cancer Res; 2021; 217():157-195. PubMed ID: 33200366
[TBL] [Abstract][Full Text] [Related]
27. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
Schellenbacher C; Roden R; Kirnbauer R
J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
[TBL] [Abstract][Full Text] [Related]
28. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
29. HPV vaccination for prevention of skin cancer.
Vinzón SE; Rösl F
Hum Vaccin Immunother; 2015; 11(2):353-7. PubMed ID: 25692212
[TBL] [Abstract][Full Text] [Related]
30. Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.
Wang JW; Wu WH; Huang TC; Wong M; Kwak K; Ozato K; Hung CF; Roden RBS
J Virol; 2018 Aug; 92(15):. PubMed ID: 29743371
[TBL] [Abstract][Full Text] [Related]
31. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.
Schellenbacher C; Huber B; Skoll M; Shafti-Keramat S; Roden RBS; Kirnbauer R
Vaccine; 2019 Jun; 37(27):3529-3534. PubMed ID: 31147274
[TBL] [Abstract][Full Text] [Related]
32. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
[TBL] [Abstract][Full Text] [Related]
33. Combination of human papillomaviruses L1 and L2 multiepitope constructs protects mice against tumor cells.
Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
Fundam Clin Pharmacol; 2021 Dec; 35(6):1055-1068. PubMed ID: 33930201
[TBL] [Abstract][Full Text] [Related]
34. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
35. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles.
Yang F; Mariz FC; Zhao X; Spagnoli G; Ottonello S; Müller M
Front Immunol; 2020; 11():606569. PubMed ID: 33343580
[TBL] [Abstract][Full Text] [Related]
36. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.
Karanam B; Jagu S; Huh WK; Roden RB
Immunol Cell Biol; 2009; 87(4):287-99. PubMed ID: 19421199
[TBL] [Abstract][Full Text] [Related]
37. Epidermodysplasia verruciformis and human papilloma virus.
Gewirtzman A; Bartlett B; Tyring S
Curr Opin Infect Dis; 2008 Apr; 21(2):141-6. PubMed ID: 18317036
[TBL] [Abstract][Full Text] [Related]
38. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
[TBL] [Abstract][Full Text] [Related]
39. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras.
Pineo CB; Hitzeroth II; Rybicki EP
Plant Biotechnol J; 2013 Oct; 11(8):964-75. PubMed ID: 23924054
[TBL] [Abstract][Full Text] [Related]
40. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
